证券代码：000990 证券简称：诚志股份 公告编号：2025-028 诚志股份有限公司（以下简称"公司"）控股子公司南京诚志永清能源科技 有限公司（以下简称"诚志永清"）于近期收到国家税务总局南京市税务局稽查 局《税务事项通知书》（宁税稽税通[2025]20 号）（以下简称《通知书》）， 并就《通知书》相关内容进行了自查以及税款补缴，现将有关事项公告如下： 一、自查及税款补缴情况 经自查，诚志永清需对碳五重质烃产品补缴消费税、税金附加及相关滞纳金， 总金额共计 16,635.20 万元。截至本公告披露日，诚志永清已完成相关款项的 全额缴纳，当地主管税务部门未对该事项给予处罚。 二、对公司的影响 依据《企业会计准则》的相关规定，子公司诚志永清补缴的上述款项不属于 前期会计差错，不涉及前期财务数据追溯调整，预计影响公司 2025 年度净利润 约 13,222.86 万元。最终结果及影响金额以年审会计师审计后的数据为准。敬请 广大投资者注意投资风险。 特此公告。 诚志股份有限公司 董事会 2025 年 5 月 30 日 诚志股份有限公司 关于子公司收到《税务事项通知书》暨补缴税款的公告 本公司及董事会全体成员保证 ...

Core Viewpoint - Chengzhi Co., Ltd. (000990) announced that its subsidiary, Nanjing Chengzhi Yongqing Energy Technology Co., Ltd., has received a tax notice requiring the payment of consumption tax, tax surcharges, and related late fees totaling 166 million yuan [1] Group 1 - The total amount to be paid includes consumption tax on carbon five heavy hydrocarbons, tax surcharges, and related late fees [1] - Chengzhi Yongqing has completed the full payment of the required amount, and the local tax authority has not imposed any penalties [1] - The expected impact on the company's net profit for the year 2025 is approximately 132 million yuan [1]

Core Insights - The NHNE China International Health Nutrition Expo held in Guangzhou from May 21 to 23, 2025, attracted over 1,200 participating companies and more than 100,000 professional attendees [1] - The product "Libos® D-Ribose Powder" by Chengzhi Life Science Technology Co., Ltd. is the first approved health food in China featuring D-Ribose as the main active ingredient, known for its dual functions of anti-fatigue and hypoxia resistance, and is making significant changes in cardiac protection [1][3] Company Development - Chengzhi Life Science Technology Co., Ltd. has been tracking nearly 300,000 effective data points in China, showing that D-Ribose improves various cardiac symptoms [6] - The company has established collaborations with Tsinghua University and Beijing Sport University to conduct clinical studies on D-Ribose's application in athletics, demonstrating its benefits in enhancing anaerobic thresholds and reducing muscle damage markers [8] - The brand "Libos" was recently recognized as the leading brand in D-Ribose products in China, with a brand awareness rate of 98.12% [8][9] Market Performance - In 2024, sales of Libos® D-Ribose Powder increased by approximately 50%, with single product sales exceeding 100 million yuan, making it a standout in its category [9] - The company has shifted its strategy from being a raw material supplier to actively engaging with consumers and promoting brand recognition [11] Industry Trends - Cardiovascular diseases remain the leading cause of death globally, with the number of deaths rising from 270 million to 540 million over the past 30 years [13] - Chengzhi Life Science aims to focus on nutritional intervention for cardiovascular disease management, leveraging D-Ribose's role in energy metabolism and mitochondrial protection [15][16] Future Strategy - The company plans to enhance brand building and develop new health products with clear mechanisms of action and sufficient clinical research to contribute to the Healthy China 2030 initiative [17]

Core Viewpoint - The company is transitioning from its initial phase of basic chemical production to a more advanced stage focused on optimizing core industries and enhancing specialized industrial chains through its "One Body, Two Wings" strategy [2][3][6]. Group 1: Project Developments - The new integrated propylene value chain project was completed in just over eight months, marking it as a significant project in Nanjing Jiangbei New Area with an investment of over 1 billion yuan [2][5]. - The project utilizes advanced international technology, producing propylene from self-sourced materials and combining it with syngas and hydrogen to manufacture octanol [5][6]. - The project achieved successful trial production and sold 80 tons of octanol on the same day, demonstrating rapid recovery of investment [5][6]. Group 2: Financial Performance - In 2021, the company's net profit reached 1.008 billion yuan, a 184.01% increase year-on-year, but fell sharply to 52.9 million yuan in 2022 due to geopolitical issues affecting coal supply and prices [3][4]. - The company aims to maintain positive cash flow and inject new growth into its operations through early revenue-generating projects like the octanol production [7][12]. Group 3: Strategic Direction - The "One Body, Two Wings" strategy encompasses clean energy and high-end chemical materials, with a focus on technological innovation and extending the industrial chain [8][9]. - The company is exploring new markets in high-performance materials, including ultra-high molecular weight polyethylene (UHMWPE) and polyolefin elastomers (POE) [7][8]. - Collaboration with academic institutions aims to enhance capabilities in synthetic biology, targeting new product development and market expansion [10][11]. Group 4: Operational Enhancements - The company is restructuring its management and talent strategy to support its upgraded operational capabilities, ensuring efficient project execution and production optimization [11][12]. - Emphasis is placed on flexible production techniques and digital management to adapt to market fluctuations and improve operational efficiency [12].

Core Viewpoint - The collaboration between Chengzhi Co., various research institutions, and universities in Yunnan focuses on the development and utilization of biodiversity and industrial hemp, aiming to integrate resources for comprehensive industry chain development [2][12]. Group 1: Collaboration Details - Chengzhi Co. signed cooperation agreements with multiple institutions, including Tsinghua University and Yunnan Agricultural Academy, to enhance industrial hemp development [1]. - The partnership aims to create a full-chain collaboration from breeding and planting to basic research, application development, and industrial transformation [2][6]. - The initiative will leverage the strengths of universities and research institutions to overcome technical bottlenecks in the industrial hemp industry [2][12]. Group 2: Research and Development Focus - Chengzhi Hanmeng Pharmaceutical will focus on key technologies such as improving CBD yield and constructing a closed-loop system for THC destruction [4]. - The collaboration will explore high-value utilization paths for agricultural waste, particularly focusing on industrial hemp stalks [5]. - Research will include the comprehensive utilization of various parts of the industrial hemp plant, establishing a full-chain system from cultivation to market application [6]. Group 3: Educational and Employment Initiatives - The partnership will establish employment and innovation practice bases to provide practical platforms for students and supply high-quality talent to enterprises [8]. - The collaboration aims to create a model for innovation cooperation between higher education institutions and industry, promoting synergy in education and research [10]. Group 4: Future Development Goals - The focus will be on technological innovation across the entire industrial hemp chain, developing high-value products, and exploring new applications in pharmaceuticals, health care, and daily chemicals [12]. - Chengzhi Co. plans to deepen cooperation with various parties to explore high-value development paths for Yunnan's unique biological resources, contributing to the high-quality development of the local bio-industry [15].

Group 1: Company Performance and Market Concerns - The company has faced allegations of mismanagement leading to a loss of nearly 10 billion in state assets, resulting in a significant decline in stock price over the years [1] - The stock price has dropped from 34 to over 7 since 2017, with a current market value of 9 billion despite financing exceeding 16 billion [2] - The company is implementing a valuation enhancement plan to address long-term stock price issues and improve shareholder returns [4] Group 2: Research and Development Investments - The company invests several billion annually in R&D, focusing on core industries to ensure sustainable development [2] - As of the end of 2024, R&D personnel represent 9.13% of the workforce, with over 30% holding master's or doctoral degrees [2] - The company aims to extend its industrial chain into high-tech fields such as clean energy and advanced semiconductor materials [2] Group 3: Management and Compensation - The management's compensation has reportedly doubled since 2017, raising concerns about the distribution of total salary among executives [2] - The company emphasizes that executive pay is linked to overall business performance and adheres to regulatory guidelines [3] Group 4: Corporate Governance and Shareholder Engagement - The company is committed to enhancing governance and operational standards to improve market value and investor confidence [4] - It plans to strengthen its long-term incentive mechanisms and explore stock buybacks to align management interests with company growth [4][5]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000990 证券简称：诚志股份 公告编号：2025-025 诚志股份有限公司 关于参加江西辖区上市公司2025年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 为进一步加强与投资者的互动交流，诚志股份有限公司（以下简称"公司"）将参加由江西省上市公司协 会举办的"2025年江西辖区上市公司投资者网上集体接待日活动"，现将相关事项公告如下： 董事会 2025年5月17日 证券代码：000990 证券简称：诚志股份 公告编号：2025-026 诚志股份有限公司关于 为子公司安徽诚志提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 诚志股份有限公司（以下简称"公司"）第八届董事会第十一次会议和公司2024年年度股东大会审议通过 了《关于公司 2025 年度为控股子公司提供担保的议案》，公司于2025年3月27日披露了《关于为控股子 公司提供担保的公告》（公告编号：2025-013 ）。 本次活动将采用网络 ...

证券代码：000990 证券简称：诚志股份 公告编号：2025-025 诚志股份有限公司 关于参加江西辖区上市公司2025年投资者 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，诚志股份有限公司（以下简称"公司"） 将参加由江西省上市公司协会举办的"2025 年江西辖区上市公司投资者网上集 体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 5 月 21 日（星期三）15:30-17:00。届 时公司董事、总裁韦俊民先生，副总裁、董事会秘书左皓先生，将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、融资计划和可持续发展等投 资者关心的问题，与投资者进行沟通与交流。 欢迎广大投资者积极参与。 特此公告。 诚志股份有限公司 董事会 2025 年 5 月 17 日 网上集体接待日活动的公告 ...

证券代码：000990 证券简称：诚志股份 公告编号：2025-026 诚志股份有限公司 关于为子公司安徽诚志提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 诚志股份有限公司（以下简称"公司"）第八届董事会第十一次会议和公司2024年 年度股东大会审议通过了《关于公司 2025 年度为控股子公司提供担保的议案》，公司于 2025年3月27日披露了《关于为控股子公司提供担保的公告》（公告编号：2025-013 ）。 现就公司为全资子公司安徽诚志显示玻璃有限公司（以下简称"安徽诚志"）提供 担保相关事项的进展情况公告如下： 一、担保情况概述 2025年5月15日，公司与合肥科技农村商业银行股份有限公司蚌埠分行签订了《最高 额保证合同》，为安徽诚志向合肥科技农村商业银行股份有限公司蚌埠分行申请的综合 授信业务提供担保，担保的债权额度为人民币2000万元。 二、担保协议的主要内容 公司与合肥科技农村商业银行股份有限公司蚌埠分行签订的《最高额保证合同》 保证人：诚志股份有限公司 债权人：合肥科技农村商业银行股份有限公司蚌埠分行 债务人：安徽诚志显示玻 ...

Group 1: Financial Performance - The company achieved a net profit of 231 million yuan in 2024, representing a year-on-year growth of 29.98% [7][10] - The goodwill at the end of 2024 was 6.728 billion yuan, a decrease of 14 million yuan compared to the previous year [10] - The company has committed to initiating cash dividend procedures when the net profit for 2025 is positive, ensuring reasonable returns for investors [3][5] Group 2: Market and Shareholder Concerns - The company's stock price has been underperforming, significantly below its net asset value, raising concerns about market perception and management effectiveness [12][21] - The major shareholder, Beijing Jinxin Zhuohua Investment Center, has reduced its holdings, which has been interpreted as a lack of confidence in the company's future [9][21] - The company is actively working on a valuation enhancement plan to improve investor confidence and reflect the company's quality [8][12] Group 3: Corporate Governance and Management - Executive compensation is linked to overall company performance and is determined based on various regulations and performance assessments [4][5] - The company emphasizes transparency in executive pay and has disclosed relevant information in its annual report [13] - The management is focused on balancing capital expenditure with shareholder returns to achieve mutual growth [3][6] Group 4: Strategic Development and Future Plans - The company is pursuing a "2.0 version" development strategy, focusing on high-end chemical materials and semiconductor display materials to enhance its market position [12][21] - Plans are in place to expand into new business areas, including synthetic biology and industrial hemp, to diversify revenue streams [13][14] - The company is investing in projects to enhance production capacity for POE and ultra-high molecular weight polyethylene, aiming to improve product competitiveness [12][21]